Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial

Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial

Objective In PAISLEY, a 48-week, phase II, randomised controlled trial that assessed deucravacitinib in patients with active SLE, all primary and secondary endpoints were met with the deucravacitinib 3 mg two times per day dose. Changes in patient-reported outcomes, collected as exploratory endpoint...

Full description

Saved in:
Bibliographic Details
Main Authors: Laurent Arnaud, Marta Mosca, Anca Askanase, Vibeke Strand, Subhashis Banerjee, Shalabh Singhal, Coburn Hobar, Samantha Pomponi, Brandon Becker, Jiyoon Choi
Format: Article
Language:English
Published: BMJ Publishing Group 2025-06-01
Series:Lupus Science and Medicine
Online Access:https://lupus.bmj.com/content/12/1/e001517.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items